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Creating biomaterials that are suited for clinical application is still hampered by a lack of understanding
of the interaction between a cell and the biomaterial surface it grows on. This surface communication can
strongly impact cellular behavior, which in turn affects the chances of a successful interaction between a
material and the host tissue. Transcriptomics data have previously been linked to measurements of
biomaterial properties in order to explain the biological mechanisms underlying these cell-biomaterial
interactions. However, such multi-assay data are highly complex and therefore require careful and un-
ambiguous characterization and storage. Failure to do so may result in loss of valuable data or erroneous
data analysis. In order to start a new initiative that tackles these issues and offers a platform for inno-
vative biomaterial development, we have created a publically accessible repository called The Com-
pendium for Biomaterial Transcriptomics (cBiT, https://cbit.maastrichtuniversity.nl). cBiT is a data
warehouse that gives users the opportunity to search through biomaterial-based transcriptomics data
sets using a web interface. Data of interest can be selected and downloaded, together with associated
measurements of material properties. Researchers are also invited to add their data to cBiT in order to
further enhance its scientific value. We aim to make cBiT the hub for biomaterial-associated data, thereby
enabling major contributions to a more efficient development of new materials with improved body
integration. Here, we describe the structure of cBiT and provide a use case with clinically applied ma-
terials to demonstrate how cBiT can be used to correlate data across transcriptomics studies.
© 2017 Elsevier Ltd. All rights reserved.1. Introduction
The last decades have seen a surge in the design and use of novel
materials for biomedical applications. While it is known that bulk
material properties and the surface communication between a cell
and the biomaterial can strongly impact cell shape, attachment,
proliferation and differentiation, the exact interaction at the
interface between cells and biomaterials is unknown and uncon-
trolled [1e4]. This often results in sub-optimal functioning of
medical implants, increased health care costs and additional pain
for the patient [5,6]. On the other hand, the knowledge gap hinders
the design of beneficial bio-active surface properties.
In order to solve these problems we need to advance our
knowledge by implementing an interdisciplinary method that(D.G.A.J. Hebels).encompasses cell biology, micro-fabrication, materials science and
computational sciences. This convergence of multiple fields of
research has been coined “materiomics” and represents a much
needed holistic approach to the investigation of biological material
systems, through the integration of biological functions and pro-
cesses with traditional materials science perspectives, such as
physical properties, chemical components, hierarchical structures,
and mechanical behavior [2].
Although the number of studies using this materiomics strategy
is still relatively limited, its frequency of use is on the rise. Espe-
cially the association of transcriptomics with material character-
ization data has been applied several times and more studies
appear every month. Transcriptomics refers to the simultaneous
measurement of all transcribed genes through either microarrays
(hybridization of the transcriptome to complementary sequences
of all known genes spotted on a glass slide) or RNA sequencing
(RNAseq, the sequencing of the full transcriptome). In our previous
D.G.A.J. Hebels et al. / Biomaterials 149 (2017) 88e97 89work, we used transcriptomics analysis and material character-
ization to investigate the biomaterial-cell interaction in more
detail. We specifically focused on linking material properties with
gene expression responses and discovered for example, a suitable
model cell type for in vitro biomaterial testing [7], physicochemical
parameters that influence differentiation [8], and possible key
players in extracellular matrix deposition associated with
osteoinduction [9]. Some of this work employs mesenchymal
stromal cells, which are considered to be a very valuable resource
for transcriptomics-based investigations of cellular processes
crucial in tissue regeneration [10]. Other groups have used a similar
approach, sometimes using different omics technologies such as
proteomics, as reviewed by Power et al. and Gallagher et al. [11,12].
Some recent examples include a transcriptomic analysis of theFig. 1. Integration of biology (left) and material science (right) towards a computation
bone fracture as an example. Both bone (left) and bone graft substitutes such as ceramics (r
measurements and gene expression in bone cells and microstructure and chemical compos
computational approaches (From Groen et al. [9]. Copyright Wiley-VCH Verlag GmbH & Coeffect of biomaterial substrate on the osteogenic differentiation of
stem cells, an examination of early cellular and molecular re-
sponses to differently modified surfaces of medical steel, and an
excellent study by Guerette et al. that integrates RNAseq with
proteomics and materials science [13e15]. Materiomics has also
been suggested as the way forward in oral disease diagnostics and
personal health monitoring [16]. Other types of high-throughput
technologies have been applied too in order to improve the effi-
ciency of biomaterial screening while simultaneously investigating
cell biology. This includes material microarrays such as the
polymer-cell interaction platform developed by Anderson et al. and
the TopoChip [17e19]. For an excellent overview of other high-
throughput approaches for screening and analysis of cell behav-
iors we refer the reader to a recent review by Seo et al. [20].al approach for new biomaterial development, using bone tissue engineering of a
ight) can be deconstructed into their elementary components, i.e. molecular cell biology
ition data of materials, respectively. The interplay between them can be studied using
. KGaA. Reproduced with permission.).
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promising, these efforts have only begun to explore the complex
relationship between cells and biomaterial properties. Moreover,
omics technologies, as well as advanced materials engineering and
characterization can generate large amounts of data on cell-
biomaterial induced gene, protein or metabolite expression and
material properties respectively. This is especially true for tran-
scriptomics data and is expected to pose amajor problem due to the
absence of a specialized repository to collect, curate, maintain and
analyze this wealth of data.
Current available repositories concentrate on either material
properties (Supplementary Table S1) or transcriptomics data
(Supplementary Table S2) without efficiently combining these data
sets. More specifically, current materials repositories largely focus
on computational material properties (e.g. Materials Project, Open
Materials Database) and only a limited set of databases contain data
on biomaterial properties (e.g. ASM Medical Materials Database,
Biomat_dBase, Biomaterials Properties Database). Similarly, a
considerable number of transcriptomics databases have been
created. The Gene Expression Omnibus (GEO) and ArrayExpress are
large, general purpose repositories but more dedicated databases
also exist, focusing on gene expression in different species (e.g.
Bgee), in cancer (e.g. Genomic Data Commons), the effect of small
molecules (e.g. Connectivity Map) or toxicity (e.g. Comparative
Toxicogenomics Database, diXa). While some of these repositories
have the option of including metadata, such as material properties,
this is not their main purpose and is therefore not done in a stan-
dardized and organized fashion, limiting an integrated analysis of
data from multiple sources. Moreover, current materials re-
positories have a similarly narrow focus on just one piece of the
puzzle, ignoring the biological questions at the root of the cell-
biomaterial interface. A higher level of organization is required to
solve this issue, similar to the initiatives taken by the zebrafish
(https://zfin.org/) and yeast (http://www.yeastgenome.org/)
research communities.
We therefore propose the establishment of a dedicated tran-
scriptomics repository that offers an innovative strategy to improve
material development while at the same time providing novel in-
sights into the complex signaling pathways that drive the cell's
response to biomaterials (Fig. 1), thereby following the principles ofFig. 2. Data in cBiT will be archived in a standardized way, allowing for efficient data
archives. Once deposited, queries can be made and single or multiple data sets can be dow
tool to improve their research, ultimately contributing to new cell biology knowledge and/materiomics. In the long run, such an initiative could contribute to a
more efficient development of new biomaterials that perform even
better in patients. To reach this goal we present here the Com-
pendium for Biomaterial Transcriptomics (cBiT), a publicly acces-
sible data repository directed at collecting transcriptomics data and
carefully recorded material properties and other relevant metadata
(https://cbit.maastrichtuniversity.nl). A cBiT introduction video,
explaining the background and goal of the repository, can be found
here: https://www.youtube.com/watch?v¼O12dPthanrM. Within
cBiT we aim to generate and collect unique and standardized
knowledge on how different cell types interact with awide range of
commonly used biomaterials. By generating new information and
simultaneously accumulating it in an open access repository, we
expect that it will be possible to predict cell response to bio-
materials in the near future. A prediction approach towards
biomaterial development can drastically reduce the current time
and development costs, while at the same time ensuring higher
clinical success rates. Moreover, in silico predictions will be essen-
tial to advance biomaterials science since the number of possible
combinations of surface and chemistry properties far exceeds what
could realistically be tested in vitro or in vivo.
The open access aspect of this repository will stimulate the
development of new and better materials by allowing researchers
to freely use data from the repository and compare their own data
with repository data sets. Indeed, combining data from different
studies for meta-analysis purposes has repeatedly been shown to
lead to improved data interpretation [21e24]. Researchers are also
invited to submit their own data to cBiT. To ensure an unambiguous
characterization of data files and experiment characteristics, ISA-
Tab-based data archives for each incorporated study are used
[25]. There will be control on data completeness and standardiza-
tion of study properties through the use of ISA tools. Ultimately, the
repository-associated research could lead to the identification of
genes, pathways, expression profiles or specific material properties
that can inform the design and development of new implant bio-
materials with excellent in vivo properties (Fig. 2).2. Data infrastructure and use
cBiT comprises a central warehouse containing data fromanalysis strategies. Biomaterial studies can be incorporated into cBiT using ISA-Tab
nloaded for a wide array of analysis options. This provides scientists with a powerful
or new biomaterial development.
Fig. 4. An overview of cBiT's content and web interface.
Fig. 3. Schematic overview of the cBiT data infrastructure. After data collection of a transcriptomics experiment and subsequent archive preparation, the data are first imported into
the institutional DataHub repository (which also serves as a back-up) [26], followed by import into cBiT where the data are processed and indexed to enable search queries and
downloads.
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D.G.A.J. Hebels et al. / Biomaterials 149 (2017) 88e9792transcriptomics studies. An overview of cBiT's infrastructure, from
data set creation to integration and finally data download, is shown
in Fig. 3.
2.1. Data sources
Currently, 8 studies including 296 samples and involving 17
different biomaterials originating from various transcriptomics
projects, are deposited in cBiT. The data included in cBiT so far, have
all been generated through in vitro microarray-based tran-
scriptomics experiments covering 7 cell lines. An overview of what
is currently covered by the data sets in cBiT is shown in Fig. 4. Each
data set added to cBiT is first prepared in ISA-Tab format [27]. ISA-
Tab is a tabular format, designed to be used in scientific fields to
organize data into standardized data archives that distinguish be-
tween the “Investigation” (the project context), “Study” (a unit of
research) and “Assay” (analytical measurement) data. This careful
detailing of data archives ensures the re-usability of the data which
is one of the key principles of the FAIR initiative [28]. The FAIR data
principles act as an international guideline for high quality data
stewardship ensuring that data are Findable, Accessible, Interop-
erable, and Re-usable. Other cBiT characteristics, such as its use of
standard file formats, official ontology terms, and the open access
structure, all contribute to meeting the FAIR principles. Further-
more, FAIR-inspired improvements, such as the addition of digital
object identifiers (DOI's) to data sets, will be implemented in the
near future.
cBiT was designed to include all the essential information about
transcriptomics experiments as also implemented in repositories
such as GEO or ArrayExpress. This involves following the MIAME
(Minimum Information About a Microarray Experiment) and
MINSEQE (Minimum Information about a high-throughput nucle-
otide SEQuencing Experiment) guidelines that enable the inter-
pretation of the results of the experiment unambiguously andmake
it possible to reproduce the experiment [29]. Furthermore, we
encourage the use of ISO standards such as described in ISO 10993,
Biological evaluation of medical devices [30]. cBiT could thereby
contribute to the goals of ISO to standardize material testing when
studies incorporated in cBiT use, for example, cell types or cell lines
which have been approved by ISO.
Although cBiT so far only contains microarray-based tran-
scriptomics studies, our repository has been designed to also
incorporate RNAseq datawhichwill be included soon. Both raw and
processed microarray data are available for download. RNAseq-
based transcriptomics studies on the other hand will only offer
the processed data since the raw data can be very large in size
which could use up toomuch bandwidth. Instead, raw RNAseq data
will be uploaded into ArrayExpress or GEO (Gene Expression
Omnibus) and a link to these files will be provided within cBiT.
Regarding microarray platform compatibility, cBiT can incorporate
Illumina, Affymetrix, and Agilent data. For future RNAseq data, the
focus will first be on the Illumina platform, but other platforms can
also be included.
Data on biomaterial properties are either included in tabular
format (for single numerical and categorical properties) or in a
separate metadata file, containing more complex data, such as
graphs or images. For instance, cBiT now contains 2 studies which
incorporate graph-based data. Since samples are identically enco-
ded in both the transcriptomics and biomaterial properties data, a
download of a specific set of samples will always contain both types
of data for the samples requested.
2.2. Web interface
The cBiT Welcome page can be found at https://cbit.maastrichtuniversity.nl and contains a short video describing the
story behind cBiT. The About tab contains some additional infor-
mation and a manual on how to use cBiT, while a Frequently Asked
Questions (FAQ) list can be found in the FAQ tab. Exploring the
content of cBiT and searching for studies with specific details can be
done in the Browse tab. As a default, in the results section on the
right side of the screen, all available studies are shown as “study
cards” with the title, the authors involved, and a collapsible over-
view of the samples in each study. All studies can be downloaded
directly, without performing any queries, using the Download
button in each study card. However, if a user wants to perform a
specific query, there are two ways to search through the cBiT data
sets:
(1) Use the free-text search field in the upper left corner of the
screen to look for specific study terms. Most study properties
are indexed when new data sets are integrated into cBiT and
can be queried using free-text input. The results section on
the right immediately updates to display the subset of
studies and samples matching the search query.
(2) Use the facetted quick selection menu on the left of the
screen to narrow down studies. The menu items correspond
with study properties and selecting/de-selecting items will
immediately update the results section to display studies and
samples that match the selection criteria. Properties are
divided into Material, Biological, and Technical Properties
and further sub-categories per item. An overview of all
available biomaterial properties included in cBiT is shown
under “Full list of properties” in the Browse tab.
By default, the control samples corresponding to any of the
queried samples are automatically included in the search results.
This function can be switched off by unchecking the “Include
associated controls” check box. Next, studies or specific samples in
the results section can be added to the Download box shown in the
upper right corner of the screen. Clicking on this box allows the
user one final check of the selection after which a zip archive is
prepared which can be downloaded. The zip archive contains the
raw and normalized transcriptomics data, the study protocols, the
study properties, including all measured material properties, and
any additional supplementary files.2.3. Quality control and pre-processing
Data in cBiT have undergone a quality control check and a
platform-specific pre-processing procedure that is also described in
detail in the protocols associated with each study. Quality control is
based on an evaluation of raw and normalized data density plots,
cumulative distribution function (CDF) plots, MA plots, clustering
and principal component analysis (PCA) plots. If these plots show
any strong outliers, the data of the corresponding sample will not
be included in the archive. Pre-processing of raw data consists of a
platform-specific normalization and a data transformation (e.g.
log2, vst, etc.).
Other research groups who are interested in uploading their
study to cBiT are also invited to contact us. We have detailed in-
structions prepared on how to accurately prepare the data ac-
cording to our standards using template files (available for
download in the About tab). All submissions will be manually
curated and any data inconsistencies will be checked and corrected
in collaboration with the submitting party. Quality control of the
transcriptomics data, as described above, will also be performed,
thereby assuring high quality error-free data.
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Research groups who would like to integrate their data in cBiT,
can already submit their data set before any accompanying
manuscript is published. The data set can be put on hold and made
publicly accessible once the data are published. This is in agreement
with the aforementioned FAIR andMIAME/MINSEQE guidelines but
also with an increasing number of journals that consider full data
availability a prerequisite. The copyright of any submitted data will
remain with the submitting party and any request to withdraw a
data set from cBiT will be met immediately. However, it is the au-
thors' responsibility to make sure this does not interfere with the
data policy of the institution or the journal inwhich themanuscript
was published.
With regard to data permissions, especially data based on hu-
man samples, it is the submitting party's responsibility to ensure
that the submitted information does not compromise participant
privacy and is in accord with the original consent in addition to all
applicable laws, regulations, and institutional policies.
3. Study properties
Each cBiT study contains a wide range of material, biological,
and technical properties that offer detailed measurements of spe-
cific material properties and contain biological and technical details
on the biological material(s) used. We made a pre-selection of
widely used properties, but these are in no way restrictive and any
property can be added if required. When preparing a study for
upload into cBiT, these study properties are all integrated into our
standardized ISA-Tab format, ensuring comparability across
studies.Where possible, official ontology terms are used to describe
properties (derived from the EMBL-EBI Ontology Lookup Service,
http://www.ebi.ac.uk/ols).
3.1. Material properties
Under material properties, all types of material measurements
can be included. Four sub-categories exist for General, Chemical,
Physical, and Mechanical properties. When building an ISA-Tab
archive, the measurement device and unit of measurement are
also recorded and will be part of the eventual download. Simple
numerical data are included as a table, but more complex graph-
based data can also be included as a supplementary Excel file.
3.2. Biological properties
The biological properties contain all relevant information on the
biological material used (e.g. cell type, tissue, species, etc.) and the
culturing conditions (growth medium, cell attachment, growthTable 1
List of file types typically present in a cBiT download.
File type Description
field_descriptions.tsv Alphabetical list of all study properties contained in the
i_Investigation.txt The study protocols and some additional information on
sample_info.csv Values of all measured or documented study properties
Biomaterial graphs filea A separate metadata Excel file, containing more complex
Supplementary filea One or more supplementary files containing additional m
graphs file.
Raw data file(s)b The raw data file(s) of the transcriptomics assay correspo
Processed data file The processed data file(s) of the transcriptomics assay cor
as normalization
Annotation file Additional annotations for the genes in the raw and proc
a Not always present.
b Not present for RNAseq data.duration, compound exposure, etc.). Together with the study pro-
tocols included in each download, this contains all the information
for a user to repeat the experiment.3.3. Technical properties
The technical properties contain all relevant information on the
transcriptomics technique used (e.g. platform, chip type) and de-
tails on the data processing such as background correction, type of
normalization, and type of data transformation. Together with the
study protocols included in each download, this contains all the
information for a user to repeat the data processing.3.4. Supplementary info
In addition to the optional inclusion of a supplementary Excel
file for graph-based material property data, other supplementary
info can also be incorporated in a study. Possibilities include RT-PCR
data, Western blot images, ELISA's, colorimetric assays, etc. When
available, files containing such data are part of the download.4. Current developments
cBiT is a stable and long-term data repository that will continue
to be updated with new biomaterial-based transcriptomics data
archives. Our aim is to reach 30 studies in 2020. Since tran-
scriptomics are the most actively produced omics data they are a
great starting point and within a year cBiT will also be storing the
first RNAseq data archives. However, in the future, cBiT can be
adapted to also house other omics data, such as proteomics, epi-
genomics, or metabolomics data. This would require only minor
modifications to the underlying data infrastructure and would
make valuable new data accessible to the research community. The
combined analysis of multi-omics data would also enable a true
systems biology approach towards cell-biomaterial interactions.
We invite research groups who are interested in depositing their
biomaterial-associated data in a sustainable repository andwho are
eager to contribute to the cBiT project, to contact us. It is possible
for them to either deposit their own data, or provide us with bio-
materials that have clinical potential which we will proceed to
investigate, analyze, and incorporate into cBiT. This can also include
data analysis of data already present in cBiT. In short, the possi-
bilities offered by cBiT are:
1. Browse, download and analyze data yourself
2. Browse, download and find an external party to analyze the data
3. Contact us with an interesting question and ask us to analyze
cBiT datadownload
associated publications
for the selected samples in the study, i.e. the metadata
study property data, such as graphs or images
easured or relevant data, not included in the sample_info.csv file or Biomaterial
nding with the selected samples
responding with the selected samples and having undergone processing steps such
essed data files (e.g. EntrezGene ID, Gene Symbol, etc.)
Fig. 5. A use case of cBiT data. (A) PCA of gene expression profiles of mesenchymal stem cells on distinct titanium surfaces. Ti ¼ titanium (Straumann), Pt ¼ pre-treated (flat),
S ¼ sand-blasted, SLA ¼ sand-blasted acid etched, flat ¼ titanium-coated flat polystyrene, dex ¼ dexamethasone. (B) Top 10 of differentially expressed up- and downregulated genes
on two distinct titanium surfaces. (C) Venn diagram of the DEGs. (D) Detail of interaction network based on the DEGs (full network in Supplementary Fig. S1). Blue ¼ unique for SLA,
green ¼ unique for dexamethasone, red ¼ overlapping between both. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of
this article.)
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data
5. Upload your own data set
With cBiT we also aim to make a first attempt at dealing with
systematic characterization of material properties. Comparison of
material-based studies, even those using the same material, can be
problematic due to ambiguous or inaccurate recording of material
properties, used instruments or units of measurement. With our
ISA-Tab archives, which require a careful documentation of all
relevant details, this incertitude can be diminished. We hope that
this lays the foundation for an internationally recognized and
standardized biomaterial ontology.
Considering cBiT's goal of driving the discovery of useful ma-
terials or material properties that have desirable biological
outcome parameters, the eventual integration of cBiT with analysis
tools that assist in this identification process is obvious. For
example, the Connectivity Map tool which compares expression
profiles of small molecule-exposed transcriptomics data with the
user's input profile could be easily adapted to screen tran-
scriptomics data from cells grown on new potentially promising
biomaterials against the biomaterial-induced expression profiles
from cBiT [31].
As cBiT expands, clinical application will always be the focus
point. Materials currently being used in a wide range of clinical
settings are prime candidates for inclusion in cBiT. Using the
knowledge accumulated in cBiT, newly developed materials can
eventually find their way to the patient again.
5. Use case
To illustrate its ease of use and provide an example of cBiT's
potential, we present here a use case to show how cBiT's data can
be used to provide biological insight into biomaterial-cell in-
teractions. In this scenario, we were interested in exploring the
effect of titanium on osteoinductive differentiation of mesen-
chymal stem cells (MSCs). We started off by typing in “titanium” in
the Browse tab's upper left search box. We then narrowed the
search results down by selecting only studies using human
mesenchymal stromal cells (hMSC) by selecting only that option
under Biological Properties > Cell strain. We left the default option
to include associated controls active. Two studies using MSCs
showed up including a total of 51 samples: one study using tita-
nium surfaces created by the dental implant manufacturer Strau-
mann (Study 1) and one study using titanium-coated polystyrene
surfaces which also includes samples exposed to dexamethasone, a
positive control for osteoinduction (Study 2). Since the dexameth-
asone expression pattern forms an interesting osteoinduction
reference profile for comparison with the Straumann gene
expression patterns, we selected both studies for download by
clicking on the green “þ” button. At this point, the user has the
option tomanually remove or add specific samples in each study by
clicking on the “matching samples” dropdown list in the study card.
Using this possibility, in Study 2, we decided to only include the
samples using a flat surface and dexamethasone and not the
microstructured surface (called “Ti1018”), by unchecking the
microstructure samples leaving a total of 42 samples. Next, by
clicking the white/green plus button of both studies, the selected
samples were added to the download box in the upper right corner
and subsequently downloaded as a zip file. The unzipped file
contains a separate “field_descriptions.tsv” file and two folders
with the selected samples of the two studies including a small
number of info files. An overview of possible file types in a typical
download is shown in Table 1.
Although the downloaded data already contain processed data,users may prefer to do their own data processing. Hence, we used
the raw data in this use case and processed them using the online
gene expression analysis tool ArrayAnalysis (http://arrayanalysis.
org/) [32]. The two studies were processed separately using the
“Illumina QC and pre-processing” module. Data were already
background subtracted (as indicated in the “sample_info.csv” file)
and as further processing steps, quantile normalization and
variance-stabilizing transformation (VST) were applied, while
filtering out genes not reaching the detection threshold (i.e.
detection p-value 0.01). A principal component analysis (PCA),
shown in Fig. 5A, shows the separation of the different conditions.
The two processed data sets were subsequently analyzed
separately using the “Statistical analysis” module in ArrayAnalysis
(a linear model using the R package limma). To keep this example
concise, we limited the analysis to the 5 days growth conditions in
both studies. In Study 1 we selected the sandblasted (S) titanium
and sandblasted-acid etched (SLA) titanium conditions and in
Study 2 the flat titanium-coated surface with dexamethasone
condition and compared them with their respective control con-
ditions. As a cut-off for differential expression, an adjusted p-value
(Benjamini-Hochberg) of <0.05 and an absolute fold change of >1.5
was used. The differentially expressed genes (DEGs) on the S sur-
face, the SLA surface, and the dexamethasone-induced osteoin-
duction reference profile were subsequently compared.
The top 10 of differentially up- and downregulated genes for
both studies and a Venn diagram with the DEGs overlap between
the three conditions are shown in Fig. 5B and C respectively. The
SLA surface affects almost every gene the S surface also regulates,
but overall has a much stronger effect on the gene expression
pattern, regulating an additional 146 genes. Interestingly, the SLA
surface genes also show a considerable overlap with the genes
regulated by dexamethasone (65 out of 404 genes). To visualize this
overlap better we proceeded to build separate networks with the
SLA and dexamethasone genes using the online tool Con-
sensusPathDB [33], imported the networks into CytoScape [34],
merged them, and visualized the genes' origins by color as shown in
Fig. 5D and Supplementary Fig. S1. A quick examination of the
entire network reveals that the overlapping genes between the two
networks include several multi-edge node genes which are likely to
be key players in the osteogenic response. These genes include
FBLN1 (Fibulin 1), HBEGF (Heparin-binding EGF-like growth fac-
tor), SPP1 (Osteopontin), PLAUS (Plasminogen activator, urokinase
receptor), CXCL8 (C-X-C Motif Chemokine Ligand 8), and ASS1
(Argininosuccinate synthase 1). FBLN1, HBEGF, SPP1, PLAUS, and
CXCL8 indeed have a clear relation with either osteogenesis or
osteoclastogenesis [35e39]. This relationship is less clear for the
ASS1 gene and therefore makes it an interesting candidate for
further analysis. For the sake of brevity, we will not explore these
data further here, but with this use case we have shown that a
relatively simple combined analysis of cBiT data sets (time spent
from data query to network construction was approximately
4 hours) can generate promising hypotheses for further testing.
6. Limitations and recommendations
cBiT offers an innovative new platform for biomaterial-based
transcriptomics data and has the potential to more efficiently
drive biomaterial development forward and increase our under-
standing of the mechanisms involved in cell-biomaterial in-
teractions. Despite these possibilities, there are some limitations to
be considered when using cBiT.
Transcriptomics data have a well-known drawback that applies
to the interpretation of gene expression values. Gene expression
takes place at themRNA level and therefore does not guarantee that
a working end product (i.e. a protein) will be formed that has a
D.G.A.J. Hebels et al. / Biomaterials 149 (2017) 88e9796measurable biological effect. Post-translational protein modifica-
tions and modulating miRNA's are two notable processes that can
prevent a fully functional protein product from being formed. There
are several ways to overcome these data interpretation problems
though. Firstly, in follow-up assays, protein products of differen-
tially expressed genes of interest could be detected using for
example Western blotting or immunohistochemistry. However,
this is only aworkable solutionwhen small numbers of proteins are
being detected. A multi-omics approach that combines tran-
scriptomics, proteomics and miRNA regulomics in a single experi-
ment would open up the dark box betweenmRNA expression levels
and protein end products. Although this is a very costly undertak-
ing, it also offers possibilities for data analysis that, while very
complex, are sure to result in groundbreaking insights. In addition,
the added advantage of the centralized storage of transcriptomics
data sets is that it facilitates meta-analyses which increase statis-
tical power and make significant hits more likely to have a
detectable biological outcome.
Other solutions can be found in the computational approaches
used. For example, transcriptomics-based pathway over-
representation or enrichment analyses can assist in finding
affected biological processes instead of single genes. Since signifi-
cantly modified pathways always contain a set of differentially
expressed genes (instead of just a single gene), the likelihood of all
these genes not being translated to a protein and thereby not
affecting the pathway in question, becomes much less. Other
computational approaches can be applied when the biological
significance of the gene expression data is less important and the
data are just being used as an expression profile that is character-
istic of, for example, the response of cells to a certain material
property. In such cases, the expression profiles can be used as
biomarkers of material properties. Whether the genes expressed in
these profiles are eventually translated to proteins becomes irrel-
evant then.
Regardless of these options though, when drawing conclusions
from solely gene expression data, it is always wise to consider them
as hypotheses in need of further testing and confirmation rather
than biological facts.
Another limitation of cBiT concerns the (current lack of)
biomaterial standardization. More specifically, in order to perform
in-depth meta-analyses comparing several transcriptomics studies,
it is essential that (1) crucial biomaterial parameters are charac-
terized and (2) that the biomaterial characterization is standard-
ized. This is presently not the case and even when these details
have been recorded, comparability of similar materials between
different labs is often quite poor. However, through the use of pre-
defined fields in the cBiT user interface, we stimulate an extensive
experimental characterization and a consistent description thereof.
We also highly encourage cBiT users to apply available standards
(developed, among others, by the American Society for Testing and
Materialse ASTM) or to contribute to the standardization endeavor
by developing new standards. Future developments of cBiT will
focus on including standards as metadata files. Finally, meta-
analyses of the data stored in cBiT can help to identify which
biomaterial properties are crucial and should therefore be
standardized.
7. Conclusion
We present the cBiT repository as a new tool to help researchers
in finding (1) unique and standardized knowledge on the interac-
tion of commonly used biomaterials with different cell types and
(2) insight into the underlying biological responses. It is the first
time that such a valuable combination of data is available for
download in one central location. It is our goal to quickly expandcBiT with more data on exciting new materials, increasing its sci-
entific value. At the MERLN Institute for Technology-inspired
Regenerative Medicine in Maastricht, The Netherlands, we will
continue to generate such data as part of our ongoing research but
we also invite scientists from all over the world to contribute to
cBiT. By becoming the go-to resource for biomaterial-associated
data, we expect to make a major contribution to a more efficient
development of new and better materials that show improved
integration in the human body.
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